Results overview: Found 8 records in 0.02 seconds.
Articles, 8 records found
Articles 8 records found  
1.
8 p, 985.7 KB Analysis of alternative splicing events for cancer diagnosis using a multiplexing nanophotonic biosensor / Sánchez Huertas, César (Institut Català de Nanociència i Nanotecnologia) ; Domínguez Zotes, Santos (Institut Català de Nanociència i Nanotecnologia) ; Lechuga, Laura M. (Institut Català de Nanociència i Nanotecnologia)
Personalized medicine is a promising tool not only for prevention, screening and development of more efficient treatment strategies, but also for diminishing the side effects caused by current therapies. [...]
2017 - 10.1038/srep41368
Scientific Reports, Vol. 7 (January 2017) , art. 41368  
2.
10 p, 290.8 KB Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer / Peters, S. (Lausanne University Hospital) ; Camidge, D.R. (University of Colorado) ; Shaw, A.T. (Massachusetts General Hospital) ; Gadgeel, S. (University of Michigan) ; Ahn, J.S. (Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Kim, D.W. (Seoul National University Hospital) ; Ou, S.H.I. (School of Medicine) ; Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ; Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zeaiter, A. (F. Hoffmann–La Roche) ; Mitry, E. (F. Hoffmann–La Roche) ; Golding, S. (F. Hoffmann–La Roche) ; Balas, B. (F. Hoffmann–La Roche) ; Noe, J. (F. Hoffmann–La Roche) ; Morcos, P.N. (Roche Innovation Center) ; Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). [...]
2017 - 10.1056/NEJMoa1704795
New England Journal of Medicine, Vol. 377 Núm. 9 (31 2017) , p. 829-838  
3.
12 p, 1.3 MB Surface modification of microparticles causes differential uptake responses in normal and tumoral human breast epithelial cells / Patiño Padial, Tania (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Soriano Martín, Jorge (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Barrios, L. (Leonardo) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Ibáñez, Elena (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Nogués, C. (Carme) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia)
The use of micro- and nanodevices as multifunctional systems for biomedical applications has experienced an exponential growth during the past decades. Although a large number of studies have focused on the design and fabrication of new micro- and nanosystems capable of developing multiple functions, a deeper understanding of their interaction with cells is required. [...]
2015 - 10.1038/srep11371
Scientific Reports, Vol. 5 (June 2015) , art. 11371  
4.
7 p, 508.5 KB Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk / Figlioli, Gisella (University of Pisa. Department of Biology) ; Chen, Bowang (German Cancer Research Center (DKFZ). Molecular Genetic Epidemiology (Germany)) ; Elisei, Rossella (University of Pisa. Department of Endocrinology and Metabolism (Italy)) ; Romei, Cristina (University of Pisa. Department of Endocrinology and Metabolism (Italy)) ; Campo, Chiara (University of Pisa. Department of Biology (Italy)) ; Cipollini, Monica (University of Pisa. Department of Biology (Italy)) ; Cristaudo, Alfonso (University of Pisa. Department of Endocrinology and Metabolism (Italy)) ; Bambi, Franco (Blood Centre, Azienda Ospedaliero Universitaria A. Meyer (Italy)) ; Paolicchi, Elisa (University of Pisa. Department of Biology (Italy)) ; Hoffmann, Per (University of Basel. Department of Biomedicine (Switzerland)) ; Herms, Stefan (University of Basel. Department of Biomedicine (Switzerland)) ; Kalemba, Michał (Maria Sklodowska-Curie Memorial Cancer Center. Department of Nuclear Medicine and Endocrine Oncology (Poland)) ; Kula, Dorota (Maria Sklodowska-Curie Memorial Cancer Center. Department of Nuclear Medicine and Endocrine Oncology (Poland)) ; Pastor Benito, Susana (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Marcos Dauder, Ricardo (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Velázquez Henar, María Antonia (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Jarząb, Barbara (Maria Sklodowska-Curie Memorial Cancer Center. Department of Nuclear Medicine and Endocrine Oncology (Poland)) ; Landi, Stefano (University of Pisa. Department of Biology (Italy)) ; Hemminki, Kari (Lund University. Center for Primary Health Care Research, Clinical Research Center (Sweden)) ; Gemignani, Federica (University of Pisa. Department of Biology (Italy)) ; Försti, Asta (Lund University. Center for Primary Health Care Research, Clinical Research Center (Sweden))
A genome-wide association study (GWAS) performed on a high-incidence Italian population followed by replications on low-incidence cohorts suggested a strong association of differentiated thyroid cancer (DTC) with single nucleotide polymorphisms (SNPs) at 9q22. [...]
2015 - 10.1038/srep08922
Scientific Reports, Vol. 5 (March 2015) , art. 8922  
5.
11 p, 1.0 MB ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer / Cedó, Lidia (Institut d'Investigació Biomèdica Sant Pau) ; García León, Annabel (Institut d'Investigacions Biomèdiques Sant Pau) ; Baila Rueda, Lucía (Hospital Universitario Miguel Servet) ; Santos, David (Institut d'Investigacions Biomèdiques Sant Pau) ; Grijalva, Victor (University of California. Department of Medicine) ; Martínez Cignoni, Melanie Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Carbó, José María (Universitat de Barcelona) ; Metso, Jari (Minerva Foundation Institute for Medical Research) ; López Vilaró, Laura (Institut d'Investigacions Biomèdiques Sant Pau) ; Zorzano Olarte, Antonio (Institute for Research in Biomedicine) ; Valledor, Annabel F. (Universitat de Barcelona) ; Cenarro, Ana (Hospital Universitario Miguel Servet) ; Jauhiainen, Matti (Minerva Foundation Institute for Medical Research) ; Lerma Puertas, Enrique (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Fogelman, Alan M. (University of California. Department of Medicine) ; Reddy, Srinivasa T. (University of California. Department of Medicine) ; Escolà-Gil, Joan Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. [...]
2016 - 10.1038/srep36387
Scientific Reports, Vol. 6 (November 2016) , art. 36387  
6.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analia (Hospital Universitari Vall Hebron) ; Seoane Suárez, Joan (Vall Hebron. Institut d'Oncologia (VHIO)) ; Braña, Irene (Hospital Universitari Vall Hebron) ; Sicart, Elisabet (Hospital Universitari Vall Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  
7.
11 p, 409.0 KB Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain : a multicentre observational study / Bonfill Cosp, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Martinez Zapata, María José (Universitat Autònoma de Barcelona) ; Vernooij, Robin WM (Institut d'Investigació Biomèdica Sant Pau) ; Sánchez, María José (Instituto de Investigación Biosanitaria de Granada) ; Suárez Varela, María Morales (Universitat de Valencia. Departament de Medicina Preventiva) ; de la Cruz, Javier (Hospital 12 de Octubre, Madrid) ; Emparanza, José Ignacio (Hospital Universitario Donostia) ; Ferrer, Montserrat (IMIM (Hospital del Mar Medical Research Institute)) ; Pijoán, José Ignacio (Unidad de Epidemiología Clínica y Soporte Metodológico, UICEC de BioCruces-SCReN, Barakaldo) ; Ramos Goñi, Juan M. (Health Services Research on Chronic Patients Network (REDISSEC)) ; Palou, Joan (Institut d'Investigació Biomèdica Sant Pau) ; Schmidt, Stefanie (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Abraira, Víctor (Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal) ; Zamora, Javier (Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal)
Little is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment. [...]
2015 - 10.1186/s12894-015-0058-x
BMC Urology, Vol. 15 (july 2015)  
8.
7 p, 184.9 KB Trisomy 8, a cytogenetic abnormality in Myelodysplastic Syndromes, is constitutional or not? / Saumell i Tutusaus, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ; Solé Ristol, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arenillas, Leonor (Hospital del Mar. Laboratori de Citologia Hematològica i Citogenètica Molecular) ; Montoro Gómez, Julia (Hospital Universitari Vall d'Hebron) ; Valcarcel Ferreiras, David (Hospital Universitari Vall d'Hebron) ; Pedro, Carme (Institut Hospital del Mar d'Investigacions Mèdiques) ; Sanzo, Carmen (Hospital Universitario Central de Asturias (Oviedo)) ; Luño, Elisa (Hospital Universitario Central de Asturias (Oviedo)) ; Giménez, Teresa (Hospital Universitari de Tarragona Joan XXIII) ; Arnan, Montserrat (Institut Català d'Oncologia. Hospital Duran i Reynals (L'Hospitalet de Llobregat, Barcelona)) ; Pomares, Helena (Institut Català d'Oncologia. Hospital Duran i Reynals (L'Hospitalet de Llobregat, Barcelona)) ; De Paz, Raquel (Hospital Universitario La Paz (Madrid)) ; Arrizabalaga, Beatriz (Hospital Universitario Cruces (Barakaldo, Biscaia)) ; Jerez, Andrés (Hospital General Universitario Morales Meseguer (Múrcia)) ; Martínez, Ana B. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Sánchez-Castro, Judith (Hospital Universitari Arnau de Vilanova (Lleida, Catalunya)) ; Rodríguez-Gambarte, Juan D. (Hospital Ramón y Cajal (Madrid)) ; Raya, José M. (Hospital Universitario de Canarias (Santa Cruz de Tenerife)) ; Ríos, Eduardo (Hospital de Valme (Sevilla)) ; Rodríguez-Rivera, María (Hospital del Mar. Laboratori de Citologia Hematològica i Citogenètica Molecular) ; Espinet i Solà, Blanca (Hospital del Mar. Laboratori de Citologia Hematològica i Citogenètica Molecular) ; Florensa, L. (Hospital del Mar. Laboratori de Citologia Hematològica i Citogenètica Molecular)
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). [...]
2015 - 10.1371/journal.pone.0129375
PLoS One, Vol. 10, No 6 (June 2015) , p. e0129375  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.